MAHWAH, N.J. , Aug.
19, 2024 /PRNewswire/ -- Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce it has launched 1 Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% (OTC); compare to the active ingredient in Pataday ®2 Twice Daily Relief.
According to Nielsen® syndicated data for the latest 52 weeks' period ending July 13, 2024 , the Pataday ® Twice Daily Relief (OTC) market 3 achieved annual sales of approximately $26.4 million *. Commenting on the launch, Fabio Moreno , Head – OTC Sales & Marketing, Glenmark Pharmaceuticals Inc.
said, "We are excited to announce the launch of Olopatadine Ophthalmic Solution USP, 0.1%, addressing the growing demand for a new supplier in this category. This addition highlights our commitment to meeting market needs and providing high-quality over-the-counter solutions for our customers.
" For product information and how to purchase, please visit: https://glenmarkpharma-us.com/opatadine . About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (BSE: 532296) (NSE: GLENMARK) is a research–led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. Glenmark Therapeutics Inc.
is a subsidiary of Glenmark Pharmaceuticals Ltd. The company has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 C.